Company Profile
ProMIS™ Neurosciences, Inc., headquartered in Toronto Ontario, and with offices in Cambridge Massachusetts, is publicly traded on the Toronto Stock Exchange (ticker symbol: PMN.TO) and Nasdaq (ticker symbol: PMN). ProMIS is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD).
Latest Presentation
Industry Classifications
Sector:
Healthcare
Industry:
Biotechnology
NAICS:
Pharmaceutical Preparation Manufacturing (325412)
SIC:
Pharmaceutical and Medicine Industry (3741)
Contact Information
Investor Relations
Stern Investor Relations
Suzanne Messere
Managing Director
T: 212-698-9901
suzanne.messere@sternir.com
Company Contact
ProMIS Neurosciences, Inc.
1920 Yonge Street
Suite 200
Toronto, ON M4S 3E2
Canada
T: 416-847-6898
F: 416-847-6899